Effectiveness comparison between ustekinumab and infliximab for Crohn's disease complicated with intestinal stenosis: a multicenter real-world study.

Furthermore, the 24-week steroid-free clinical remission rate, as well as the 12-week and 24-week clinical response rates, was all higher in the UST group compared to those in the IFX group; however, these differences did not reach statistical significance in our subgroup analysis results ( p > 0.05) ( Supplemental Table S4 ).

also in 111,027 other papers